Private Capital Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Private Capital Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$12K	Hold	206	–	–	0.01%	993
2022 Q1	$15K	Sell	206 -2	-1%	-$139	﹤0.01%	1130
2021 Q4	$18K	Buy	208 +2	+1%	+$163	﹤0.01%	1103
2021 Q3	$19K	Sell	206 -2	-1%	-$181	﹤0.01%	1107
2021 Q2	$20K	Sell	208 -7	-3%	-$729	﹤0.01%	1103
2021 Q1	$24K	Sell	215 -325	-60%	-$44.2K	0.01%	976
2020 Q4	$75K	Sell	540 -1	-0.2%	-$119	0.01%	611
2020 Q3	$44K	Buy	541 +13	+2%	+$1.08K	0.01%	783
2020 Q2	$41K	Buy	528 +20	+4%	+$1.32K	0.01%	809
2020 Q1	$23K	Buy	508 +174	+52%	+$9.03K	0.01%	970
2019 Q4	$14K	Buy	334 +300	+882%	+$12.4K	﹤0.01%	1229
2019 Q3	$2K	Hold	34	–	–	﹤0.01%	1915
2019 Q2	$3K	Hold	34	–	–	﹤0.01%	1831
2019 Q1	$2K	Hold	34	–	–	﹤0.01%	1918
2018 Q4	$1K	Hold	34	–	–	﹤0.01%	2083
2018 Q3	$2K	Hold	34	–	–	﹤0.01%	1967
2018 Q2	$2K	Hold	34	–	–	﹤0.01%	1916
2018 Q1	$2K	Sell	34 -1,466	-98%	-$73.8K	﹤0.01%	1862
2017 Q4	$2K	Buy	+1,500	New	+$73.5K	﹤0.01%	1847

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Private Capital Group's RARE Position: Q2 2022 in Review

Private Capital Group held its Ultragenyx Pharmaceutical (RARE) position steady in Q2 2022 at 206 shares worth $12K. The position accounts for 0.01% of the portfolio, ranked #993.

Private Capital Group first reported a position in RARE in Q4 2017 and has held it in 19 quarters since. The position peaked at $75K in Q4 2020. 224 funds tracked by Wall St. Rank hold RARE as of Q2 2022.

Private Capital Group held 206 shares of Ultragenyx Pharmaceutical worth $12K as of Q2 2022.
Private Capital Group left its Ultragenyx Pharmaceutical share count unchanged in Q2 2022.
Ultragenyx Pharmaceutical made up 0.01% of Private Capital Group's portfolio in Q2 2022, its #993 holding.
Private Capital Group first reported a position in Ultragenyx Pharmaceutical in Q4 2017 and has held it in 19 quarters since.
Private Capital Group's Ultragenyx Pharmaceutical position peaked at $75K in Q4 2020.
224 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.